Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. C-21
2. C-21 Sodium
3. C21
4. C21 Sodium
5. Compound 21
6. Compound 21 Sodium
1. 477775-14-7
2. Compound 21
3. At2 Agonist C21
4. Buloxibutid
5. At2 Receptor Agonist C21
6. M 24
7. C-21
8. Rc2v4w0eyc
9. Chembl189568
10. T2 Agonist Compound 21
11. Compound 21 [pmid: 22802221]
12. M-24
13. Butyl N-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate
14. Butyl 3-(4-((1h-imidazol-1-yl)methyl)phenyl)-5-isobutylthiophen-2-ylsulfonylcarbamate
15. Butyl ((3-(4-((1h-imidazol-1-yl)methyl)phenyl)-5-isobutylthiophen-2-yl)sulfonyl)carbamate
16. N-[[3-[4-(1h-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)-2-thienyl]sulfonyl]carbamic Acid Butyl Ester
17. Butyl [3-[4-[(1h-imidazol-1-yl)methyl]phenyl]-5-isobutylthiophen-2-yl]sulfonylcarbamate
18. Carbamic Acid, ((3-(4-(1h-imidazol-1-ylmethyl)phenyl)-5-(2-methylpropyl)-2-thienyl)sulfonyl)-, Butyl Ester
19. Carbamic Acid, [[3-[4-(1h-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)-2-thienyl]sulfonyl]-, Butyl Ester
20. Buloxibutid [inn]
21. 3-[4-(1h-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(n-butyloxylcarbamate)-sulphonamide] Sodium Salt
22. Unii-rc2v4w0eyc
23. Schembl557591
24. Gtpl6918
25. C 21 [who-dd]
26. Xteojpuyzwexfi-uhfffaoysa-n
27. Bcp30872
28. Cua77514
29. Bdbm50156173
30. Akos030231077
31. At18254
32. Sb18730
33. Ncgc00386668-01
34. M024/c21
35. Ms-28827
36. Ds-017243
37. Hy-100113
38. Cs-0018094
39. M-024
40. M 24;m-24;m24;c-21
41. Q27076423
42. N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide
43. (1-((2''-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1h-imidazol-5-yl)methanol
44. Butyl [3-{4-[(1h-imidazol-1-yl)methyl]phenyl}-5-(2-methylpropyl)thiophene-2-sulfonyl]carbamate
45. Butyl N-{3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-ylsulfonyl}carbamate
46. Carbamic Acid, [[3-[4-(1h-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)-2-thienyl]sulfon Yl]-, Butyl Ester
47. Carbamic Acid,[[3-[4-(1h-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)-2-thienyl]sulfonyl]-, Butyl Ester
| Molecular Weight | 475.6 g/mol |
|---|---|
| Molecular Formula | C23H29N3O4S2 |
| XLogP3 | 5.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 11 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 127 |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 690 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
30
PharmaCompass offers a list of Buloxibutid API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Buloxibutid manufacturer or Buloxibutid supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Buloxibutid manufacturer or Buloxibutid supplier.
PharmaCompass also assists you with knowing the Buloxibutid API Price utilized in the formulation of products. Buloxibutid API Price is not always fixed or binding as the Buloxibutid Price is obtained through a variety of data sources. The Buloxibutid Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A M024/C21 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of M024/C21, including repackagers and relabelers. The FDA regulates M024/C21 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. M024/C21 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A M024/C21 supplier is an individual or a company that provides M024/C21 active pharmaceutical ingredient (API) or M024/C21 finished formulations upon request. The M024/C21 suppliers may include M024/C21 API manufacturers, exporters, distributors and traders.
M024/C21 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of M024/C21 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right M024/C21 GMP manufacturer or M024/C21 GMP API supplier for your needs.
A M024/C21 CoA (Certificate of Analysis) is a formal document that attests to M024/C21's compliance with M024/C21 specifications and serves as a tool for batch-level quality control.
M024/C21 CoA mostly includes findings from lab analyses of a specific batch. For each M024/C21 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
M024/C21 may be tested according to a variety of international standards, such as European Pharmacopoeia (M024/C21 EP), M024/C21 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (M024/C21 USP).
